Medicine for treating neurasthenia and preparation method of medicine

A neurasthenia and drug technology, applied in the field of neurology, can solve the problems of prolonged neurasthenia, poor curative effect, drug dependence, etc., and achieve the effects of strong analgesic effect, short course of treatment and quick effect.

Active Publication Date: 2019-03-15
范崇桂
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] In terms of treatment, modern medicine advocates the use of psychotherapy on the one hand, and chemical drug treatment on the other hand. Chemical drugs have only symptomatic therapeutic effects on neurasthenia. At present, the most used anti-anxiety agents, such as tranquilizers, can improve neurological symptoms. It weakens the patient's mood, relaxes muscles, and calms and h

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0032] The invention provides a medicine for treating neurasthenia, which comprises the following components (by mass percentage): trimetazine: 2%, midecamycin: 5%, teabutetone: 30%, taurine: 17%, Ketotifen: 2%, catechin: 25%, niacinamide: 3%, oleanolic acid: 3%, quetiapine: 1.5%, loxoprofen: 11.5%.

[0033] Further, the drug for treating neurasthenia is in oral dosage form, and the oral dosage form is a tablet; the adult dosage of the drug for treating neurasthenia is 2.6mg / kg / day.

[0034] A preparation method of a medicine for treating neurasthenia in neurology, comprising the following steps:

[0035] Step 1: material preparation: get trimetazine, midecamycin, tea bumetone, taurine, ketotifen, catechin, nicotinamide, oleanolic acid, quetiapine and loxoprofen in parts by weight , respectively spare;

[0036] Step 2: Drying and grinding into powder: trimetazine, midecamycin, tea bumetone, taurine, ketotifen, catechin, nicotinamide, oleanolic acid, quetiapine and loxolo Fe...

Embodiment 2

[0042] A medicine for treating neurasthenia, comprising the following components (by mass percentage): trimetozine: 3%, midecamycin: 2%, teabumetone: 35%, taurine: 16%, ketotifen : 4%, catechin: 24%, niacinamide: 4%, oleanolic acid: 2%, quetiapine: 2%, loxoprofen: 8%.

[0043] Further, the drug for treating neurasthenia is in oral dosage form, and the oral dosage form is a tablet; the adult dosage of the drug for treating neurasthenia is 2.7mg / kg / day.

[0044] A preparation method of a medicine for treating neurasthenia, comprising the following steps:

[0045] Step 1: material preparation: get trimetazine, midecamycin, tea bumetone, taurine, ketotifen, catechin, nicotinamide, oleanolic acid, quetiapine and loxoprofen in parts by weight , respectively spare;

[0046] Step 2: Drying and grinding into powder: trimetazine, midecamycin, tea bumetone, taurine, ketotifen, catechin, nicotinamide, oleanolic acid, quetiapine and loxolo Fen is dried in an oven at 60-80°C, then cooled...

Embodiment 3

[0052] A medicine for treating neurasthenia, comprising the following components (by mass percentage): trimetazine: 4%, midecamycin: 1%, teabumetone: 40%, taurine: 15%, ketotifen : 6%, catechin: 23%, niacinamide: 5%, oleanolic acid: 1%, quetiapine: 2.5%, loxoprofen: 2.5%.

[0053] Further, the drug for treating neurasthenia is in oral dosage form, and the oral dosage form is a tablet; the adult dosage of the drug for treating neurasthenia is 2.8mg / kg / day.

[0054] A preparation method of a medicine for treating neurasthenia, comprising the following steps:

[0055] Step 1: material preparation: get trimetazine, midecamycin, tea bumetone, taurine, ketotifen, catechin, nicotinamide, oleanolic acid, quetiapine and loxoprofen in parts by weight , respectively spare;

[0056] Step 2: Drying and grinding into powder: trimetazine, midecamycin, tea bumetone, taurine, ketotifen, catechin, nicotinamide, oleanolic acid, quetiapine and loxolo Fen is dried in an oven at 60-80°C, then co...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Cumulative average particle sizeaaaaaaaaaa
Particle sizeaaaaaaaaaa
Login to view more

Abstract

The invention relates to the technical field of the neurology department, in particular to a medicine for treating neurasthenia. The medicine is prepared from components in percentage by mass as follows: 2%-4% of trimetozine, 1%-5% of midecamycin, 30%-40% of nabumetone, 15%-17% of taurine, 2%-6% of ketotifen, 23%-25% of catechol, 3%-5% of nicotinamide, 1%-3% of oleanolic acid, 1.5%-2.5% of quetiapine and 2.5%-11.5% of loxoprofen. The invention also discloses a preparation method of the medicine. The medicine comprises the steps as follows: step 1, preparing materials; step 2, drying and grinding the materials into powder; step 3, performing crushing treatment; step 4, preparing an ethanol solution; step 5, performing concentration and drying; step 6, extracting the medicine. The medicine can effectively improve organism functions and enhance immunity, has significant effects on the neurasthenia, has no toxic or side effects on the human body, can relieve anxiety and cognitive defect symptoms and has effects of clearing heat, reducing internal heat, regulating flow of vital energy and dredging collaterals.

Description

technical field [0001] The invention relates to the technical field of neurology, in particular to a medicine for treating neurasthenia and a preparation method thereof. Background technique [0002] Neurasthenia is a relatively broad term, and currently usually includes some depression, anxiety disorders, tension headaches, insomnia, indigestion, etc. Neurasthenia refers to the phenomenon of mental excitability and mental fatigue due to long-term tension and pressure, often accompanied by emotional troubles, irritability, sleep disturbance, muscle tension pain, etc. These symptoms cannot be attributed to brain, physical diseases or other diseases. Mental diseases, symptoms are mild and severe, fluctuations are related to psychosocial factors, and the course of the disease is often protracted. [0003] In terms of treatment, modern medicine advocates the use of psychotherapy on the one hand, and chemical drug treatment on the other hand. Chemical drugs have only symptomatic...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/7048A61P25/20A61K31/12A61K31/185A61K31/192A61K31/353A61K31/4535A61K31/455A61K31/495A61K31/554A61K31/56
CPCA61K31/12A61K31/185A61K31/192A61K31/353A61K31/4535A61K31/455A61K31/495A61K31/554A61K31/56A61K31/7048A61P25/20A61K2300/00
Inventor 范崇桂
Owner 范崇桂
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap